FGF2 and cancer: Here we first identified SFO as an inducer of EndoMT in the presence of serum and FGF-2 to mimic the in vivo condition, to determine whether SFO could provide a useful chemical tool to study the molecular mechanisms of the EndoMT for therapeutics for the treatment of cancer and fibrosis disease.